^
Association details:
| Biomarker: | MSI-H/dMMR |
|---|---|
| Cancer: | Solid Tumor |
| Drug: | Imfinzi (durvalumab) (PD-L1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Durvalumab for MSI-H or POLE Mutated Metastatic Colorectal Cancer
Excerpt:
...Mismatch repair deficient or microsatellite instable (defined below), or POLE mutated tumors A....
Trial ID:
Source:
Title:
Evaluate the Efficacy of MEDI4736 in Immunological Subsets of Advanced Colorectal Cancer
Excerpt:
...- Microsatelite-high colorectal cancer (also known as MSI-H, DNA mismatch repair deficient, or sometimes Lynch syndrome); or increased Tumor-Infiltrating Lymphocytes in an archived tumor specimen or fresh biopsy....
Trial ID:
More C2 evidence
Source:
Title:
Durvalumab-based immunotherapy in combination with chemoradiation for patients with early stage esophageal adenocarcinoma
Excerpt:
...Rate of cCR/pCR at 1, 2 and 3 years after start of treatment (long term follow up)Subgroup analysis of cCR/pCR rate at time of endoscopic re-evaluation and after 1 year according to following characteristics: MSI high, PD-L1 CPS>1 and PD-L1 CPS>5 and especially acc. ...
Trial ID:
Less C2 evidence
Source:
Title:
Efficacy, safety and biomarker analysis of durvalumab in patients with mismatch-repair deficient or microsatellite instability-high solid tumours
Published date:
03/04/2023
Excerpt:
Patients with dMMR/MSI-H solid tumours....Durvalumab was generally well-tolerated and provided durable responses in pre-treated patients with dMMR/MSI-H solid tumours.
DOI:
10.1186/s12885-023-10663-2
Trial ID:
Source:
Title:
124P - Durvalumab in advanced, pre-treated microsatellite instability-high solid tumors: Results of a tumor-agnostic DRUP trial cohort
Published date:
09/05/2022
Excerpt:
24 evaluable pts with 10 different cancer types were included: colorectal (n=7), bile duct (n=3), breast (n=2), endometrial (n=2), gastric (n=3), small intestine (n=3), glioblastoma (n=1), neuroendocrine (n=1), pancreatic (n=1) and prostate (n=1). CB was observed in 13 pts (54%) with an OR in 7 (29%). Median progression-free survival was 5 months (95% CI 2-not reached) and median overall survival was 26 months (95% CI 9-not reached). No unexpected toxicity was observed. WGS was successfully performed in 17 pts and confirmed MSI-H in 88%. Durvalumab provided durable responses in pts with advanced dMMR/MSI-H solid tumors and was well-tolerated. Higher SVTMB and the presence of JAK1 mutations were associated with a lack of CB; however, larger studies are warranted to validate these findings.
Trial ID:
Source:
Title:
Safety and clinical activity of durvalumab monotherapy in patients with microsatellite instability–high (MSI-H) tumors.
Excerpt:
Durvalumab had a tolerable safety profile, and showed promising antitumor activity and overall survival in patients with MSI-H tumors.
